查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611860

萬古黴素市場：按類型、劑型、給藥途徑、應用、分銷管道 - 全球預測 2025-2030

Vancomycin Market by Type (Ampicillin, Chloramphenicol, Daptomycin), Form (Capsule, Oral Solution (Liquid), Powder), Route of Administration, Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年萬古黴素市值為6.9323億美元，預計2024年將達到7.4153億美元，複合年成長率為5.26%，預計到2030年將達到9.9287億美元。

萬古黴素是一種強效抗生素，主要用於治療嚴重的細菌感染疾病，特別是對其他抗生素抗藥性的革蘭氏陽性菌感染疾病，例如抗藥性金黃色葡萄球菌(MRSA)。作為360iResearch的市場研究分析師，有必要認知到它對於治療細菌性心內膜炎和骨髓炎等危及生命的疾病是必要的。應用範圍遍及醫療機構，包括醫院、診所和專科醫療單位，並針對需要靜脈給藥的嚴重感染疾病患者。最終用途領域包括醫療保健提供者、製藥公司、研究機構等。抗生素抗藥性感染疾病的增加、抗菌藥物管理意識的增強以及藥物開發技術的進步推動了市場的發展。對有效治療通訊協定的需求也不斷成長，以解決門診和住院環境中的慢性和急性感染疾病。主要商機包括開發提高萬古黴素功效的製劑，包括組合療法和新型藥物輸送系統，例如靶向奈米載體。對市場相關人員的建議包括投資此類研發以及探索與生技公司的合作。挑戰包括萬古黴素的潛在副作用，例如腎毒性，以及由於抗藥性細菌的增加而需要繼續開發新的抗生素。醫藥品認證過程中的監管障礙也對市場擴張構成了障礙。創新機會包括開發新的協同效應製劑、最佳化劑量策略以盡量減少副作用，以及開發快速診斷方法以更精確地客製化萬古黴素治療。萬古黴素市場競爭激烈，相關人員必須優先考慮策略夥伴關係和產品創新，才能在不斷成長但嚴格監管的市場中保持競爭力。解決這些因素將有助於維持成長並有效擴大市場範圍。

主要市場統計
基準年[2023] 6.9323 億美元
預計年份 [2024] 74153萬美元
預測年份 [2030] 99287萬美元
複合年成長率（%） 5.26%

市場動態：揭示快速發展的萬古黴素市場的關鍵市場洞察

萬古黴素市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球細菌感染疾病流行不斷擴大
    • 政府的感染控制優勢策略
    • 對學名藥的需求不斷成長
  • 市場限制因素
    • 萬古黴素對健康的不良影響
  • 市場機會
    • 最佳化萬古黴素劑量的創新方法
    • 正確使用萬古黴素的有前途的教育舉措
  • 市場挑戰
    • 萬古黴素替代品的存在

波特的五力：駕馭萬古黴素市場的策略工具

波特的五力架構是了解萬古黴素市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解萬古黴素市場的外部影響

外部宏觀環境因素對萬古黴素市場表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解萬古黴素市場競爭狀況

萬古黴素市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣萬古黴素市場供應商的績效評估

FPNV定位矩陣是評估萬古黴素市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了萬古黴素市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，萬古黴素市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地細菌感染疾病的盛行率增加
      • 政府首選的感染控制策略
      • 對非專利替代品的需求不斷成長
    • 抑制因素
      • 萬古黴素對健康的不良影響
    • 機會
      • 最佳化萬古黴素輸送的創新方法
      • 為正確使用萬古黴素而進行的教育工作有希望
    • 任務
      • 萬古黴素的潛在替代品的存在
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章萬古黴素市場：依類型

  • Ampicillin
  • 氯黴素
  • Daptomycin
  • Linezolid
  • 奎奴普丁

第7章 萬古黴素市場：依形式

  • 膠囊
  • 口服溶液（液體）
  • 粉末

第8章萬古黴素市場：依給藥途徑

  • 靜脈
  • 口服

第9章萬古黴素市場：依應用分類

  • 結腸炎和腸道發炎
  • 肺部感染疾病
  • 敗血症
  • 皮膚和軟組織感染疾病

第10章萬古黴素市場：依分銷管道分類

  • 門診藥房
  • 醫院藥房
  • 網路藥房

第11章 美洲萬古黴素市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章 亞太地區萬古黴素市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東、非洲萬古黴素市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alvogen
  • Aphios Corporation
  • CJ CheilJedang Corporation
  • Eli Lilly and Company
  • Enanta Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Helix BioMedix, Inc.
  • Innovation Pharmaceuticals Inc.
  • LegoChem Biosciences, Inc.
  • Lytix Biopharma AS
  • MGB Biopharma
  • Microbiotix, Inc.
  • MicuRx Pharmaceuticals
  • Nabriva Therapeutics GmbH
  • North China Pharmaceutical Group Co., Ltd.
  • NovaBay Pharmaceuticals, Inc.
  • NovoBiotic Pharmaceuticals, LLC
  • Oragenics, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sealife Pharma GmbH
  • VIANEX
  • Xellia Pharmaceuticals ApS
  • Zealand Pharma A/S
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Zhejiang Pharmaceutical Co., Ltd.
Product Code: MRR-C002B1C99629

The Vancomycin Market was valued at USD 693.23 million in 2023, expected to reach USD 741.53 million in 2024, and is projected to grow at a CAGR of 5.26%, to USD 992.87 million by 2030.

Vancomycin is a potent antibiotic primarily used to treat severe bacterial infections, especially those caused by Gram-positive bacteria resistant to other antibiotics, such as Methicillin-resistant Staphylococcus aureus (MRSA). As a market research analyst at 360iResearch, it's vital to recognize its necessity for treating life-threatening conditions like bacterial endocarditis and osteomyelitis. The application scope extends across healthcare settings, including hospitals, clinics, and specialized healthcare units, targeting patients with serious infections that necessitate intravenous drug delivery. End-use segments include healthcare providers, pharmaceutical companies, and research institutes. The market is fueled by the increasing prevalence of antibiotic-resistant infections, growing awareness of antimicrobial stewardship, and advancements in drug development technologies. There is also rising demand for efficient treatment protocols to combat chronic and acute infections in outpatient and inpatient settings. Key opportunities include developing formulations that enhance vancomycin's efficacy, such as combinatorial therapies and novel drug delivery systems like targeted nanocarriers. Recommendations for market players involve investing in such R&D and exploring collaborations with biotechnology firms. Challenges include vancomycin's potential side effects, such as nephrotoxicity, and the rising bacterial resistance to its use, which necessitates the continuous development of novel antibiotics. Regulatory hurdles in drug approval processes also pose a barrier to market expansion. Innovation opportunities lie in creating new synergistic formulations, optimizing dosing strategies to minimize side effects, and developing rapid diagnostics to tailor vancomycin therapy more precisely. The nature of the vancomycin market is highly competitive and requires stakeholders to prioritize strategic partnerships and product innovation to maintain competitive edges in a market that is both growing but tightly monitored by regulatory agencies. Addressing these factors can help in sustaining growth and expanding market reach effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 693.23 million
Estimated Year [2024] USD 741.53 million
Forecast Year [2030] USD 992.87 million
CAGR (%) 5.26%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vancomycin Market

The Vancomycin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of bacterial infections across the globe
    • Favorable government strategies for infection control
    • Rising need for generic alternatives
  • Market Restraints
    • Adverse health impacts of vancomycin
  • Market Opportunities
    • Innovative approaches to optimize the delivery of vancomycin
    • Promising educational initiatives for adequate vancomycin use
  • Market Challenges
    • Presence of alternative substitutes of vancomycin

Porter's Five Forces: A Strategic Tool for Navigating the Vancomycin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vancomycin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vancomycin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vancomycin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vancomycin Market

A detailed market share analysis in the Vancomycin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vancomycin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vancomycin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vancomycin Market

A strategic analysis of the Vancomycin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vancomycin Market, highlighting leading vendors and their innovative profiles. These include Alvogen, Aphios Corporation, CJ CheilJedang Corporation, Eli Lilly and Company, Enanta Pharmaceuticals, Inc., GlaxoSmithKline PLC, Helix BioMedix, Inc., Innovation Pharmaceuticals Inc., LegoChem Biosciences, Inc., Lytix Biopharma AS, MGB Biopharma, Microbiotix, Inc., MicuRx Pharmaceuticals, Nabriva Therapeutics GmbH, North China Pharmaceutical Group Co., Ltd., NovaBay Pharmaceuticals, Inc., NovoBiotic Pharmaceuticals, LLC, Oragenics, Inc., Pfizer Inc., Sanofi SA, Sealife Pharma GmbH, VIANEX, Xellia Pharmaceuticals ApS, Zealand Pharma A/S, Zhejiang Hisun Pharmaceutical Co., Ltd., and Zhejiang Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Vancomycin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Ampicillin, Chloramphenicol, Daptomycin, Linezolid, and Quinupristin.
  • Based on Form, market is studied across Capsule, Oral Solution (Liquid), and Powder.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on Application, market is studied across Colitis & Intestinal Inflammation, Lung Infection, Sepsis, and Skin Soft Tissue Infection.
  • Based on Distribution Channel, market is studied across Ambulatory Pharmacy, Hospital Pharmacy, and Online Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of bacterial infections across the globe
      • 5.1.1.2. Favorable government strategies for infection control
      • 5.1.1.3. Rising need for generic alternatives
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse health impacts of vancomycin
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative approaches to optimize the delivery of vancomycin
      • 5.1.3.2. Promising educational initiatives for adequate vancomycin use
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of alternative substitutes of vancomycin
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vancomycin Market, by Type

  • 6.1. Introduction
  • 6.2. Ampicillin
  • 6.3. Chloramphenicol
  • 6.4. Daptomycin
  • 6.5. Linezolid
  • 6.6. Quinupristin

7. Vancomycin Market, by Form

  • 7.1. Introduction
  • 7.2. Capsule
  • 7.3. Oral Solution (Liquid)
  • 7.4. Powder

8. Vancomycin Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. Vancomycin Market, by Application

  • 9.1. Introduction
  • 9.2. Colitis & Intestinal Inflammation
  • 9.3. Lung Infection
  • 9.4. Sepsis
  • 9.5. Skin Soft Tissue Infection

10. Vancomycin Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Ambulatory Pharmacy
  • 10.3. Hospital Pharmacy
  • 10.4. Online Pharmacy

11. Americas Vancomycin Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Vancomycin Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Vancomycin Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alvogen
  • 2. Aphios Corporation
  • 3. CJ CheilJedang Corporation
  • 4. Eli Lilly and Company
  • 5. Enanta Pharmaceuticals, Inc.
  • 6. GlaxoSmithKline PLC
  • 7. Helix BioMedix, Inc.
  • 8. Innovation Pharmaceuticals Inc.
  • 9. LegoChem Biosciences, Inc.
  • 10. Lytix Biopharma AS
  • 11. MGB Biopharma
  • 12. Microbiotix, Inc.
  • 13. MicuRx Pharmaceuticals
  • 14. Nabriva Therapeutics GmbH
  • 15. North China Pharmaceutical Group Co., Ltd.
  • 16. NovaBay Pharmaceuticals, Inc.
  • 17. NovoBiotic Pharmaceuticals, LLC
  • 18. Oragenics, Inc.
  • 19. Pfizer Inc.
  • 20. Sanofi SA
  • 21. Sealife Pharma GmbH
  • 22. VIANEX
  • 23. Xellia Pharmaceuticals ApS
  • 24. Zealand Pharma A/S
  • 25. Zhejiang Hisun Pharmaceutical Co., Ltd.
  • 26. Zhejiang Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. VANCOMYCIN MARKET RESEARCH PROCESS
  • FIGURE 2. VANCOMYCIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VANCOMYCIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VANCOMYCIN MARKET DYNAMICS
  • TABLE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY AMPICILLIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY CHLORAMPHENICOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY QUINUPRISTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL SOLUTION (LIQUID), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VANCOMYCIN MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VANCOMYCIN MARKET SIZE, BY COLITIS & INTESTINAL INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VANCOMYCIN MARKET SIZE, BY LUNG INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VANCOMYCIN MARKET SIZE, BY SEPSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VANCOMYCIN MARKET SIZE, BY SKIN SOFT TISSUE INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, 2023